Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Parasit Vectors ; 11(1): 265, 2018 04 24.
Article in English | MEDLINE | ID: mdl-29690907

ABSTRACT

BACKGROUND: The Esmeraldas focus of onchocerciasis in Ecuador expanded geographically during the 1980s and was associated with severe ocular and skin disease. Mass drug administration (MDA) with ivermectin started in 1991, initially once but later twice a year, in the principle endemic focus followed by all satellite foci. Treatment was stopped in 2009 when entomological assessments determined that transmission of Onchocerca volvulus had been interrupted. METHODS: Three years after the cessation of ivermectin treatment in 2012, as defined by the WHO guidelines for onchocerciasis elimination, blackfly collections were done in four sentinel sites in former hyperendemic areas. The presence of infective larvae in local vectors, Simulium exiguum and Simulum quadrivittatum, was assessed by detection of O. volvulus DNA by PCR. Additional flies captured in four extra-sentinel sites located in former hyper- and mesoendemic dispersed isolated areas were also assessed. RESULTS: The results from 68,310 captured blackflies, 40,114 from four sentinel villages in the previously hyperendemic areas (Corriente Grande, El Tigre, San Miguel on Río Cayapas and Naranjal on Río Canandé) and 28,197 from extra-sentinel locations, were all negative for the presence of O. volvulus. These extra-sentinel sites (Hualpí on Río Hoja Blanca, Capulí on Río Onzole, La Ceiba on Río Tululví and Medianía on Río Verde) were included to provide additional evidence of the impact of MDA on the transmission of O. volvulus in isolated endemic areas. CONCLUSIONS: Our data indicate that transmission of O. volvulus has been stopped in all endemic areas in Ecuador, including all satellite foci outside the main focus. These findings indicate that a strategy of ivermectin distribution twice a year to over 85% of the treatment-eligible population was effective in eliminating the infection from Ecuador in a focus with a highly competent primary vector, S. exiguum, and where the infection rates were equal to or greater than observed in many onchocerciasis foci in Africa.


Subject(s)
Disease Eradication/organization & administration , Ivermectin/administration & dosage , Onchocerca volvulus/isolation & purification , Onchocerciasis/epidemiology , Onchocerciasis/prevention & control , Simuliidae/parasitology , Animals , Antibodies, Helminth/blood , Colombia/epidemiology , Disease Transmission, Infectious/prevention & control , Epidemiological Monitoring , Health Policy , Humans , Mass Drug Administration , Onchocerciasis/transmission
2.
PLoS Negl Trop Dis ; 8(5): e2821, 2014 May.
Article in English | MEDLINE | ID: mdl-24853587

ABSTRACT

INTRODUCTION: A clinically significant endemic focus of onchocerciasis existing in Esmeraldas Province, coastal Ecuador has been under an ivermectin mass drug administration program since 1991. The main transmitting vector in this area is the voracious blackfly, Simulium exiguum. This paper describes the assessments made that support the decision to cease mass treatment. METHODOLOGY AND PRINCIPLE FINDINGS: Thirty-five rounds of ivermectin treatment occurred between 1991-2009 with 29 of these carrying >85% coverage. Following the guidelines set by WHO for ceasing ivermectin distribution the impact on parasite transmission was measured in the two vector species by an O-150 PCR technique standard for assessing for the presence of Onchocerca volvulus. Up to seven collection sites in three major river systems were tested on four occasions between 1995 and 2008. The infectivity rates of 65.0 (CI 39-101) and 72.7 (CI 42-116) in 1995 dropped to zero at all seven collection sites by 2008. Assessment for the presence of antibodies against O. volvulus was made in 2001, 2006, 2007 and 2008 using standard ELISA assays for detecting anti-Ov16 antibodies. None of total of 1810 children aged 1-15 years (between 82 and 98% of children present in the surveyed villages) tested in the above years were found to be carrying antibodies to this antigen. These findings were the basis for the cessation of mass drug treatment with ivermectin in 2009. SIGNIFICANCE: This fulfillment of the criteria for cessation of mass distribution of ivermectin in the only known endemic zone of onchocerciasis in Ecuador moves the country into the surveillance phase of official verification for national elimination of transmission of infection. These findings indicate that ivermectin given twice a year with greater than 85% of the community can move a program to the final stages of verification of transmission interruption.


Subject(s)
Filaricides/administration & dosage , Insect Vectors/parasitology , Ivermectin/administration & dosage , Onchocerciasis/transmission , Simuliidae/parasitology , Adolescent , Animals , Antibodies, Helminth/blood , Child , Child, Preschool , Ecuador/epidemiology , Humans , Infant , Infant, Newborn , Onchocerciasis/epidemiology , Onchocerciasis/parasitology , Onchocerciasis/therapy , Preventive Health Services/methods
3.
BMC Med ; 5: 9, 2007 May 23.
Article in English | MEDLINE | ID: mdl-17521449

ABSTRACT

BACKGROUND: Onchocerciasis is a leading cause of blindness worldwide, hence elimination of the infection is an important health priority. Community-based treatment programs with ivermectin form the basis of control programs for the disease in Latin America. The long-term administration of ivermectin could eliminate Onchocerca volvulus infection from endemic areas in Latin America. METHODS: A strategy of annual to twice-annual treatments with ivermectin has been used for onchocerciasis in endemic communities in Ecuador for up to 14 years. The impact of ivermectin treatment on ocular morbidity, and O. volvulus infection and transmission was monitored in seven sentinel communities. RESULTS: Over the period 1990-2003, high rates of treatment coverage of the eligible population were maintained in endemic communities (mean 85.2% per treatment round). Ivermectin reduced the prevalence of anterior segment disease of the eye to 0% in sentinel communities and had a major impact on the prevalence and transmission of infection, with possible elimination of infection in some foci. CONCLUSION: The distribution of ivermectin in endemic communities in Ecuador might have eliminated ocular morbidity and significant progress has been made towards elimination of the infection. A strategy of more frequent treatments with ivermectin may be required in communities where the infection persists to achieve the objective of elimination of the infection from Ecuador. The elimination of the infection from an endemic country in Latin America would be a major public health achievement and could stimulate the implementation of elimination strategies in other endemic countries.


Subject(s)
Antiparasitic Agents/administration & dosage , Disease Outbreaks/prevention & control , Endemic Diseases/prevention & control , Ivermectin/administration & dosage , Onchocerciasis/drug therapy , Onchocerciasis/epidemiology , Adult , Disease Transmission, Infectious/prevention & control , Drug Administration Schedule , Ecuador/epidemiology , Female , Humans , Male , Middle Aged , Onchocerciasis/transmission , Prevalence
4.
Am J Trop Med Hyg ; 75(6): 1058-62, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17172365

ABSTRACT

World Health Organization certification criteria for onchocerciasis elimination use anterior segment eye lesion prevalence as an indicator of mass ivermectin treatment program success. Lesions either contain visible microfilaria (noninflammatory punctate keratitis [PK] or microfilariae in anterior chamber [MFAC]), or microfilaria obscured by inflammation (inflammatory PK). To assess the utility of these disease indicators, two experienced ophthalmologists independently examined persons from endemic (N = 325) and nonendemic (N = 348) Guatemalan communities. Thirty-six (11.1%) and nine (2.6%) persons from endemic and nonendemic areas respectively had lesions found by either ophthalmologist (prevalence ratio = 4.3, 95% CI 2.1-8.8, P < 0.001). All lesions in nonendemic areas were inflammatory PK in whom no persons were seropositive for onchocerciasis. Overall, observer agreement was moderate (Kappa = 0.49), and most (61%) discordance occurred with inflammatory PK lesions. Our findings suggest that inflammatory punctate keratitis is neither a specific nor a reliable indicator of onchocercal eye disease. Future prevalence surveys should rely upon noninflammatory lesions as disease indicators.


Subject(s)
Anterior Chamber/parasitology , Onchocerciasis, Ocular/pathology , Animals , Eye Diseases/parasitology , Guatemala/epidemiology , Humans , Observer Variation , Onchocerca/isolation & purification , Onchocerciasis, Ocular/epidemiology , Prevalence , Reproducibility of Results
5.
Mem. Inst. Oswaldo Cruz ; 91(2): 153-8, Mar.-Apr. 1996. tab
Article in English | LILACS | ID: lil-174369

ABSTRACT

Trends in prevalence rates of onchocercal ocular lesions were examined over the period 1980 to 1990 using data from two cross-sectional surveys. There was evidence for increasing prevalence of anterior chamber microfilariae, iridocyclitis, optic atrophy, and chorioretinopathy. Large increases in prevalence, in particular, were seen for posterior segment lesions: optic atrophy increased from 2,7 per cent to 6.4 per cent and chorioretinopathy from 8.8 per cent to 35.6 per cent. Greatest increases in these lesions were seen in the Chachi which was attributed to the large increases in prevalence of microfilariae in the anterior chamber particularly in those aged 30 years or greater. The study findings suggest that ocular onchocerciasis is evolving in parallel with the well documented parasitological changes.


Subject(s)
Humans , Onchocerciasis/epidemiology , Ecuador/epidemiology , Eye Infections, Parasitic/epidemiology , Prevalence
SELECTION OF CITATIONS
SEARCH DETAIL
...